Q&A: GSK Regulatory Head Huckle Talks About Life Under FDASIA
GlaxoSmithKline Chief Regulatory Officer Paul Huckle discusses the big pharma’s experience with the PDUFA V review “program” for new molecular entities, the “breakthrough therapy” pathway and FDA’s patient-focused drug development initiative.
You may also be interested in...
Although drugs on the FDASIA-created expedited pathway may promise more than they can deliver, it will be difficult to reduce demand for such treatments awarded the designation, Boston researchers predict in a NEJM piece.
Discrete packaging for authorized dose in 6-11 year-olds is not yet available, so vaccination providers have to use product from a vial labeled for ‘booster doses only’ in adults. ACIP members unanimously endorse use of the mRNA vaccine in individuals ages 6-17 years but urge manufacturers to move away from relying on color to differentiate formulations.
Advisory committee members cited a litany of shortfalls with efficacy data from two existing studies and say a new Phase III trial is needed in a large, ethnically and racially diverse population of Alzheimer’s disease psychosis patients.